Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Graham Capital Management L.P.

Key Points

• Graham Capital Management L.P. has significantly reduced its holdings in Teva Pharmaceutical Industries Ltd. by 53.5%, decreasing its shares from 76,232 to 35,457, as reported in its latest Form 13F filing.
• Teva's stock price was up 2.5% at $18.94, with a 1-year range between $12.47 and $22.80, indicating potential volatility in the market.
• Institutional investors own over 54% of Teva’s stock, with various firms, including Menora Mivtachim and Allspring Global Investments, increasing their positions in the company.

Graham Capital Management L.P. decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 53.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,457 shares of the company's stock after selling 40,775 shares during the period. Graham Capital Management L.P.'s holdings in Teva Pharmaceutical Industries were worth $545,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $39,000. New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $43,000. Compagnie Lombard Odier SCmA acquired a new position in Teva Pharmaceutical Industries during the first quarter worth approximately $54,000. Banque Cantonale Vaudoise acquired a new position in Teva Pharmaceutical Industries during the first quarter worth approximately $74,000. Finally, Brooklyn Investment Group increased its position in Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock worth $77,000 after purchasing an additional 4,014 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded up $0.39 on Tuesday, reaching $19.69. 12,962,752 shares of the company's stock were exchanged, compared to its average volume of 12,029,524. The firm has a market capitalization of $22.58 billion, a price-to-earnings ratio of -123.06, a PEG ratio of 1.12 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The business's 50-day moving average is $17.09 and its two-hundred day moving average is $16.41. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm's revenue was up .3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 target price for the company. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.